Increase in Shares and Capital Stock Through Exercise of Stock Acquisition Rights
First written in FY2017-Q3. 12 of 15 entries say "Advanced", first in FY2017. Latest entry: FY2025.
20 other companies' latest entry also says "Other".
- FY2025Completion of stock acquisition rights exercises, with no further increaseAnnual report
「Exercised 21,200 Expired ― Unexercised balance ―」
The remaining 21,200 Series 6 share acquisition rights were exercised, leaving no unexercised balance. No increase in stated capital from the exercise of share acquisition rights during the period was disclosed. - FY2024AdvancedAnnual report
「1 March 2023–29 February 2024 (Note 1) 24,000 24,347,800 8 906 8 841 (Note) 1 Increase due to the exercise of share acquisition rights.」
The exercise of share acquisition rights resulted in the issuance of 24,000 shares, increasing stated capital and the capital surplus by ¥8 million each. - FY2024-Q1AdvancedAnnual report
「1 March 2023–31 May 2023 (Note 2) 24,000 24,347,800 8 906 8 841 (Note) 2 Increase due to the exercise of share acquisition rights.」
During the first-quarter accounting period, 24,000 shares were issued through the exercise of share acquisition rights, increasing stated capital and the capital surplus by ¥8 million each. - FY2023AdvancedAnnual report
「1 June 2022–28 February 2023 563,100 12,161,900 377,696 898,880 377,696 833,880」
The exercise of share acquisition rights resulted in the issuance of 563,100 shares, increasing stated capital and the capital surplus by ¥377.696 million each. - FY2023-Q3AdvancedAnnual report
「1 September 2022–30 November 2022 (Note 1) 151,200 11,787,000 101,416 647,417 101,416 582,417 (Note) 1 Increase due to the exercise of share acquisition rights.」
During the third-quarter accounting period, 151,200 shares were issued through the exercise of share acquisition rights, increasing stated capital and the capital surplus by ¥101.416 million each. A further 100,000 shares were issued by the filing date. - FY2023-Q2AdvancedAnnual report
「1 June 2022–31 August 2022 (Note) 37,000 11,635,800 24,817 546,001 24,817 481,001 (Note) Increase due to the exercise of share acquisition rights.」
During the second-quarter accounting period, 37,000 shares were issued through the exercise of share acquisition rights, increasing stated capital and the capital surplus by ¥24.817 million each. - FY2022RestatedAnnual report
「Number of shares underlying share acquisition rights (shares) (Note 2) 744,000」
The filing reiterates that 744,000 shares underlying Series 6 share acquisition rights remained outstanding and unexercised at period-end. - FY2019AdvancedAnnual report
「The increase of 190,000 shares in issued common stock was due to the exercise of share acquisition rights.」
During the fiscal year, 190,000 shares were issued through the exercise of share acquisition rights, increasing stated capital and the capital surplus by ¥44.958 million each. Subsequently, the existing 535,000 Series 4 share acquisition rights expired. - FY2019-Q1AdvancedAnnual report
「1 March 2018–22 April 2018 (Note) 1 30,000 11,546,800 7,098 483,323 7,098 418,323 23 April 2018 (Note) 2 △108,000 11,438,800 － 483,323 － 418,323 24 April 2018–31 May 2018 (Note) 1 160,000 11,598,800 37,860 521,183 37,860 456,183 (Note) 1 Increase due to the exercise of share acquisition rights. 2 Decrease due to the cancellation of treasury shares.」
During the first quarter, a total of 190,000 shares were issued through the exercise of share acquisition rights, increasing stated capital and the capital surplus by ¥44.958 million each. Meanwhile, 108,000 treasury shares were cancelled. - FY2018AdvancedAnnual report
「The increase of 364,000 shares in issued common stock was due to the exercise of share acquisition rights.」
During the fiscal year, 364,000 shares were issued through the exercise of share acquisition rights, increasing stated capital and the capital surplus by ¥86.131 million each. - FY2018-Q3AdvancedAnnual report
「1 September 2017–30 November 2017 (Note) 55,200 11,401,200 13,061 448,871 13,061 383,871 (Note) Increase due to the exercise of share acquisition rights.」
During the third-quarter accounting period, 55,200 shares were issued through the exercise of share acquisition rights, increasing stated capital and the capital surplus by ¥13.061 million each. - FY2018-Q2AdvancedAnnual report
「1 June 2017–31 August 2017 (Note) 37,200 11,346,000 8,802 435,809 8,802 370,809 (Note) Increase due to the exercise of share acquisition rights.」
During the second-quarter accounting period, 37,200 shares were issued through the exercise of share acquisition rights, increasing stated capital and the capital surplus by ¥8.802 million each. - FY2018-Q1AdvancedAnnual report
「1 March 2017–19 April 2017 (Note) 1 16,000 11,294,800 3,786 393,879 3,786 328,879 21 April 2017–31 May 2017 (Note) 1 140,000 11,308,800 33,127 427,006 33,127 362,006 (Note) 1 Increase due to the exercise of share acquisition rights.」
During the first quarter, a total of 156,000 shares were issued through the exercise of share acquisition rights, increasing stated capital and the capital surplus by ¥36.913 million each. - FY2017AdvancedAnnual report
「The increase of 86,000 shares in issued common stock was due to the exercise of share acquisition rights.」
During the fiscal year, 86,000 shares were issued through the exercise of share acquisition rights, increasing stated capital and the capital surplus by ¥20.349 million each. - FY2017-Q3First statedAnnual report
「1 September 2016–30 November 2016 (Note) 26,000 11,238,800 6,152 380,628 6,152 315,628 (Note) Increase due to the exercise of share acquisition rights.」
During the third-quarter accounting period, 26,000 shares were issued through the exercise of share acquisition rights, increasing stated capital and the capital surplus by ¥6.152 million each.